

|  |  |
|--|--|
|  | <b>Office translation. In case of discrepancies, the Norwegian original version shall prevail.</b>   |
| <b>INNKALLING TIL<br/>ORDINÆR GENERALFORSAMLING</b><br><br><b>LYTIX BIOPHARMA AS</b><br>(ORG.NR. 985 889 635)  | <b>NOTICE OF<br/>ANNUAL GENERAL MEETING</b><br><br><b>LYTIX BIOPHARMA AS</b><br>(REG.NO. 985 889 635)  |
| Styret i Lytix Biopharma AS (" <b>Selskapet</b> ") innkaller herved aksjonærene til ordinær generalforsamling.   | The board of directors of Lytix Biopharma AS (the " <b>Company</b> ") hereby calls for an annual general meeting for the shareholders.   |
| <b>Tid:</b> 14. april 2026 kl. 13:00.  | <b>Time:</b> 14 April 2026 at 13:00 (CEST).  |
| <b>Sted:</b> Sandakerveien 138, Oslo, Norge.   | <b>Place:</b> Sandakerveien 138, Oslo, Norway.   |
| Generalforsamlingen vil bli åpnet av CEO, Øystein Rekdal, eller av en annen person utpekt av styret. Møteåpner vil opprette fortegnelse over møtende aksjeeiere og fullmakter. | The general meeting will be opened by the CEO, Øystein Rekdal, or the person appointed by the board of directors. The person opening the meeting will record the attendance of present shareholders and proxies.                             |
| Selskapets styre foreslår følgende dagsorden for generalforsamlingen:  | The board of directors of the Company proposes the following agenda for the general meeting:   |
| <b>1 VALG AV MØTELEDER</b>   | <b>1 ELECTION OF A PERSON TO CHAIR THE MEETING</b>   |
| Styret foreslår at Øystein Rekdal velges som møteleder.  | The board of directors proposes that Øystein Rekdal is elected to chair the meeting.   |
| <b>2 VALG AV ÉN PERSON TIL Å MEDUNDERTEGNE PROTOKOLLEN SAMMEN MED MØTELEDEREN</b>  | <b>2 ELECTION OF A PERSON TO CO-SIGN THE MINUTES TOGETHER WITH THE CHAIR OF THE MEETING</b>  |
| Styret foreslår at en person som er til stede på generalforsamlingen velges til å medundertegne protokollen.   | The board of directors proposes that a person present at the general meeting is elected to co-sign the minutes.  |
| <b>3 GODKJENNELSE AV INNKALLING OG DAGSORDEN</b>   | <b>3 APPROVAL OF NOTICE AND AGENDA</b>   |
| Styret foreslår at generalforsamlingen treffer følgende vedtak:<br><br><i>Innkallingen og dagsorden godkjennes.</i>  | The board of directors proposes that the general meeting passes the following resolution:<br><br><i>The notice and the agenda are approved.</i>  |
| <b>4 GODKJENNELSE AV ÅRSREGNSKAPET OG ÅRSBERETNINGEN FOR REGNSKAPSÅRET 2025</b>  | <b>4 APPROVAL OF THE ANNUAL ACCOUNTS AND THE ANNUAL REPORT FOR THE FINANCIAL YEAR 2025</b>   |
| Styrets forslag til årsregnskap og årsrapport for regnskapsåret 2025, herunder årsberetningen, er vedlagt denne innkallingen som <a href="#">Vedlegg 1</a> .                   | The board of directors' proposal for annual accounts and annual report for the financial year 2025, including the auditor's report, are attached to this notice as <a href="#">Appendix 1</a> .  |
| Styret foreslår at generalforsamlingen treffer følgende vedtak:<br><br><i>Selskapets årsregnskap og årsrapport, herunder årsberetning, for regnskapsåret 2025 godkjennes.</i>  | The board of directors proposes that the general meeting passes the following resolution:<br><br><i>The Company's annual accounts and annual report, including the board of directors' report, for the financial year 2025 are approved.</i> |
| <b>5 UTBYTTE</b>   | <b>5 DISTRIBUTION OF DIVIDEND</b>  |

|   |  |
|---|--|
| Styret foreslår at generalforsamlingen treffer følgende vedtak om utdeling av utbytte:  | The board of directors proposes that the general meeting passes the following resolution with respect to the distribution of dividend:   |
| <i>Det utdeles ikke utbytte for regnskapsåret 2025.</i>   | <i>Dividends will not be distributed for the financial year 2025.</i>  |
| <b>6 GODKJENNELSE AV REVISORS GODTGJØRELSE</b>  | <b>6 APPROVAL OF THE AUDITOR'S REMUNERATION</b>  |
| Styret foreslår at revisors honorar for 2025 godkjennes etter regning. Styret foreslår at generalforsamlingen treffer følgende vedtak:  | The board of directors proposes that the auditor's fee for the financial year 2025 is approved as per the auditor's invoice. The board of directors proposes that the general meeting passes the following resolution:   |
| <i>Godtgjørelse til revisor for revisjon og revisjonsrelaterte tjenester for regnskapsåret 2025 godkjennes etter regning.</i>   | <i>Remuneration to the auditor for audit and audit-related costs for the financial year 2025 based on the invoice is approved.</i>   |
| <b>7 STYREFULLMAKT TIL KAPITALFORHØYELSE - OPSJONSPROGRAM</b>   | <b>7 BOARD AUTHORISATION FOR SHARE CAPITAL INCREASE - OPTION PROGRAM</b>   |
| <b>7.1 Bakgrunn</b>   | <b>7.1 Background</b>  |
| Selskapets generalforsamling har tidligere vedtatt at Selskapet skal ha et opsjonsprogram på inntil 10 % av totalt antall utstedte aksjer i Selskapet (" <b>Opsjonsprogrammet</b> "). Styret har i henhold til generalforsamlingens vedtak 29. april 2025 en fullmakt til å forhøye aksjekapitalen med inntil NOK 682.620,00 knyttet til Opsjonsprogrammet. Fullmakten er gyldig frem til Selskapets ordinære generalforsamling i 2027, dog ikke lenger enn til 29. april 2027. | The Company's general meeting has previously resolved that the Company shall have an option program of up to 10% of the total number of issued shares in the Company (the " <b>Option Program</b> "). Pursuant to the general meeting's resolution on 29 April 2025, the board of directors has an authorization to increase the share capital by up to NOK 682,620.00 related to the Option Program. The authorization is valid until the Company's annual general meeting in 2027, but no longer than 29 April 2027. |
| <b>7.2 Ny styrefullmakt til kapitalforhøyelse - Opsjonsprogrammet</b>   | <b>7.2 New board authorization to increase the share capital - the Option Program</b>  |
| På grunn av Selskapets økte aksjekapital, utgjør ikke tidligere tildelte styrefullmakt 10 % av Selskapets aksjekapital. Styret foreslår at generalforsamlingen treffer følgende vedtak om ny styrefullmakt knyttet til Opsjonsprogrammet som skal erstatte fullmakten som utløper på tidspunkt for ordinær generalforsamling 2027:  | Due to the Company's increased share capital, the previous board authorization no longer constitutes 10% of the Company's share capital. The board of directors proposes that the general meeting passes the following resolution on a new board authorization related to the Option Program which will replace the authorization that expires at the time of the annual general meeting in 2027:  |
| (i) <i>Fra tidspunktet for registrering i Foretaksregisteret, erstatter denne fullmakten tidligere fullmakt for utstedelse av nye aksjer i forbindelse med Opsjonsprogrammet, som styret ble tildelt på den ordinære generalforsamlingen 29. april 2025.</i>  | (i) <i>From the time of registration with the Norwegian Register of Business Enterprises, this authorization replaces the previous authorization for issuance of shares in connection with the Option Program, granted to the board of directors at the annual general meeting held on 29 April 2025.</i>  |
| (ii) <i>I henhold til aksjeloven § 10-14 gis styret fullmakt til å forhøye Selskapets aksjekapital, i en eller flere omganger, med inntil NOK 769.000,05.</i>   | (ii) <i>Pursuant to Section 10-14 of the Norwegian Private Limited Liability Companies Act, the board of directors is granted an authorization to increase the Company's share capital, in one or more rounds, by up to NOK 769,000.05.</i>  |
| (iii) <i>Aksjeeiernes fortrinnsrett til å tegne de nye aksjene etter aksjeloven § 10-4 kan fravikes.</i>  | (iii) <i>The shareholders' preferential right to subscribe for the new shares pursuant to Section 10-4 of the Companies Act may be deviated from.</i>  |

|          |  |          |   |
|----------|--|----------|---|
| (iii)    | <i>Fullmakten kan kun benyttes for å utstede aksjer i forbindelse med Opsjonsprogrammet.</i>   | (iv)     | <i>The authorization may only be used to issue new shares in connection with the Option Program.</i>  |
| (iv)     | <i>Fullmakten omfatter kapitalforhøyelse mot innskudd i andre eiendeler enn penger eller rett til å pådra Selskapet særlige plikter etter aksjeloven § 10-2.</i>   | (v)      | <i>The authorization includes share capital increases against contribution in kind or the right to incur specific obligations on behalf of the Company, cf. Section 10-2 of the Companies Act.</i>  |
| (V)      | <i>Fullmakten omfatter ikke kapitalforhøyelse ved fusjon etter aksjeloven § 13-5.</i>  | (VI)     | <i>The authorization does not comprise share capital increases in connection with mergers pursuant to Section 13-5 of the Companies Act.</i>  |
| (VI)     | <i>Fullmakten gjelder fra registrering i Foretaksregisteret og frem til Selskapets ordinære generalforsamling i 2028, dog ikke lenger enn til 14. april 2028.</i>  | (VII)    | <i>The authorization shall be effective from the date it is registered in the Norwegian Register of Business Enterprises and shall be valid until the Company's annual general meeting in 2028, but no longer than 14 April 2028.</i>             |
| <b>8</b> | <b>VALG AV STYREMEDLEMMER</b>  | <b>8</b> | <b>ELECTION OF MEMBERS TO THE BOARD OF DIRECTORS</b>  |
|          | Valgkomiteens innstilling er vedlagt som Vedlegg 2.  |          | The nomination committee's recommendation is attached as Appendix 2.  |
|          | Valgkomiteen har foretatt en helhetlig vurdering av styrets sammensetning i lys av Selskapets utvikling og fremtidige behov.   |          | The nomination committee has conducted an overall assessment of the composition of the board of directors in light of the Company's development and future needs.   |
|          | Valgkomiteen foreslår at styret reduseres fra syv til seks medlemmer, for å sikre et effektivt og hensiktsmessig styre med relevant kompetanse for Selskapets videre utvikling.  |          | The nomination committee proposes to reduce the board from seven to six members in order to ensure an efficient and appropriately composed board with relevant competencies for the Company's continued development.                              |
|          | Valgkomiteen foreslår at følgende personer velges som styremedlemmer:  |          | The nomination committee proposes that the following persons be elected as members of the board of directors:   |
|          | <ul style="list-style-type: none"> <li>• Eric Falcand (styrets leder)</li> <li>• Julie Dehaene-Puype</li> <li>• Claus Andersson</li> <li>• Darlene Deptula-Hicks</li> <li>• Marie-Louise Fjällskog</li> <li>• Brynjar Forbergskog</li> </ul> |          | <ul style="list-style-type: none"> <li>• Eric Falcand (chair of the board)</li> <li>• Julie Dehaene-Puype</li> <li>• Claus Andersson</li> <li>• Darlene Deptula-Hicks</li> <li>• Marie-Louise Fjällskog</li> <li>• Brynjar Forbergskog</li> </ul> |
|          | Styret vil etter dette bestå av seks medlemmer.  |          | Following this, the board of directors will consist of six members.   |
|          | Valgkomiteen foreslår at samtlige styremedlemmer velges for en periode på to år, frem til ordinær generalforsamling i 2028.  |          | The nomination committee proposes that all board members be elected for a term of two years, until the annual general meeting in 2028.  |
|          | Valget innebærer at eventuelle gjeldende valgperioder erstattes av nye valgperioder som angitt ovenfor.  |          | The election implies that any current terms of office are replaced by the new terms set out above.  |
|          | <b>Forslag til vedtak:</b>   |          | <b>Proposed resolution:</b>   |
|          | Generalforsamlingen treffer følgende vedtak:   |          | The general meeting resolves as follows:  |

|   |  |
|---|--|
| <p>Følgende personer velges som styremedlemmer for en periode frem til ordinær generalforsamling i 2028:</p> <ul style="list-style-type: none"> <li>• Eric Falcand (styrets leder)</li> <li>• Julie Dehaene-Puype</li> <li>• Claus Andersson</li> <li>• Darlene Deptula-Hicks</li> <li>• Marie-Louise Fjällskog</li> <li>• Brynjar Forbergskog</li> </ul> | <p>The following persons are elected as members of the board of directors for a term until the annual general meeting in 2028:</p> <ul style="list-style-type: none"> <li>• Eric Falcand (chair of the board)</li> <li>• Julie Dehaene-Puype</li> <li>• Claus Andersson</li> <li>• Darlene Deptula-Hicks</li> <li>• Marie-Louise Fjällskog</li> <li>• Brynjar Forbergskog</li> </ul> |
| <p><b>9 VALG AV MEDLEMMER TIL VALGKOMITEEN</b></p>  | <p><b>9 ELECTION OF MEMBERS TO THE NOMINATION COMMITTEE</b></p>  |
| <p>På ordinær generalforsamling i 2025, ble den sittende valgkomiteén valgt for en periode på ett (1) år, frem til og med Selskapets ordinære generalforsamling i 2026.</p>   | <p>At the annual general meeting in 2025, the current nomination committee was elected for a period of one (1) year, until and including the Company's annual general meeting in 2026.</p>   |
| <p>Valgkomiteén har, i sin innstilling til generalforsamlingen, foreslått at samtlige medlemmer av valgkomiteén fortsetter sine verv frem til og med Selskapets ordinære generalforsamling i 2027.</p>  | <p>The nomination committee has, in its recommendation to the general meeting, proposed that all of the current members of the nomination committee continue their duties up to and including the Company's annual general meeting in 2027.</p>  |
| <p>Valgkomiteén foreslår således at generalforsamlingen treffer følgende vedtak:</p> <ul style="list-style-type: none"> <li>• Steinar Thoresen (valgkomiteéns leder)</li> <li>• Lise von Tangen Jordan</li> <li>• Erik Rosen</li> </ul>   | <p>Accordingly, the nomination committee proposes that the general meeting passes the following resolution:</p> <ul style="list-style-type: none"> <li>• Steinar Thoresen (chair of the nomination committee)</li> <li>• Lise von Tangen Jordan</li> <li>• Erik Rosen</li> </ul>   |
| <p>For mer informasjon, vises det til valgkomiteéns innstilling, vedlagt denne protokollen som Vedlegg 2.</p>   | <p>For more information, reference is made to the nomination committee's recommendation, attached hereto as Appendix 2.</p>  |
| <p><b>10 HONORAR TIL STYRETS MEDLEMMER</b></p>  | <p><b>10 REMUNERATION TO THE MEMBERS OF THE BOARD OF DIRECTORS</b></p>   |
| <p>Valgkomiteén foreslår at styrets leder mottar NOK 500.000 i årlig godtgjørelse, og at styremedlemmene mottar NOK 325.000 i årlig godtgjørelse for perioden fra ordinær generalforsamling i 2026 til og med ordinær generalforsamling i 2027.</p>   | <p>The nomination committee proposes an annual cash compensation of NOK 500,000 to the chair of the board and NOK 325,000 to the board members for the period from the annual general meeting in 2026 until and including the annual general meeting in 2027.</p>  |
| <p>Valgkomiteén foreslår videre at honoraret for neste periode utbetales månedlig.</p>  | <p>The nomination committee proposes that the remuneration for the next period is paid on a monthly basis.</p>   |
| <p>I samsvar med valgkomiteéns innstilling, foreslår styret at generalforsamlingen treffer følgende vedtak om honorar til styrets medlemmer:</p>  | <p>In accordance with the nomination committee's proposal, the board of directors proposes that the general meeting resolves the following regarding remuneration to the members of the board of directors:</p>  |
| <p><i>Styrets medlemmer skal motta følgende honorar i perioden fra ordinær generalforsamling i 2026 til og med ordinær generalforsamling i 2027:</i></p>  | <p><i>The members of the board of directors shall receive the following remuneration for the period from the annual general meeting in 2026 to and including the annual general meeting in 2027:</i></p>   |

|  |   |
|--|---|
| <ul style="list-style-type: none"> <li>• <i>Eric Falcand skal motta NOK 500.000</i></li> <li>• <i>Claus Andersson skal motta NOK 325.000</i></li> <li>• <i>Julie Dehaene-Puype skal motta NOK 325.000</i></li> <li>• <i>Darlene Deptula-Hicks skal motta NOK 325.000</i></li> <li>• <i>Marie-Louise Fjällskog skal motta NOK 325.000</i></li> <li>• <i>Brynjar Forbergskog skal motta NOK 325.000</i></li> </ul> | <ul style="list-style-type: none"> <li>• <i>Eric Falcand shall receive NOK 500,000</i></li> <li>• <i>Claus Andersson shall receive NOK 325,000</i></li> <li>• <i>Julie Dehaene-Puype shall receive NOK 325,000</i></li> <li>• <i>Darlene Deptula-Hicks shall receive NOK 325,000</i></li> <li>• <i>Marie-Louise Fjällskog shall receive NOK 325,000</i></li> <li>• <i>Brynjar Forbergskog shall receive NOK 325,000</i></li> </ul>  |
| <p><i>Selskapet skal utbetale godtgjørelse til styrets medlemmer på månedlig basis i perioden mellom ordinær generalforsamling i 2026 og 2027.</i></p>   | <p><i>The Company shall pay the remuneration on a monthly basis in the period between the annual general meeting in 2026 and 2027.</i></p>  |
| <p><b>11 HONORAR TIL MEDLEMMER AV VALGKOMITEEN</b></p>   | <p><b>11 REMUNERATION TO THE MEMBERS OF THE NOMINATION COMMITTEE</b></p>  |
| <p>Valgkomiteén foreslår at valgkomitéens leder skal motta NOK 90.000 i årlig godtgjørelse og at valgkomitéens medlemmer skal motta NOK 75.000 i årlig godtgjørelse for perioden fra ordinær generalforsamling i 2026 til og med ordinær generalforsamling i 2027.</p>   | <p>The nomination committee proposes an annual cash compensation of NOK 90,000 to the chair of the nomination committee and NOK 75,000 to the members of the nomination committee for the period from the annual general meeting 2026 until and including the annual general meeting in 2027.</p>   |
| <p>I samsvar med valgkomiteens innstilling foreslår styret at generalforsamlingen treffer følgende vedtak om honorar til valgkomitéens medlemmer.</p>  | <p>In accordance with the nomination committee's proposal, the board proposes that the general meeting resolves the following regarding the remuneration of the nomination committee's members:</p>   |
| <p><i>Valgkomitéens medlemmer skal motta følgende honorar i perioden fra ordinær generalforsamling i 2026 til og med ordinær generalforsamling i 2027:</i></p>   | <p><i>The members of the nomination committee shall receive the following remuneration for the period from the annual general meeting in 2026 to and including the annual general meeting in 2027:</i></p>  |
| <ul style="list-style-type: none"> <li>• <i>Steinar Thoresen skal motta NOK 90.000</i></li> <li>• <i>Lise von Tangen Jordan skal motta NOK 75.000</i></li> <li>• <i>Erik Rosen skal motta NOK 75.000</i></li> </ul>  | <ul style="list-style-type: none"> <li>• <i>Steinar Thoresen shall receive NOK 90,000</i></li> <li>• <i>Lise von Tangen Jordan shall receive NOK 75,000</i></li> <li>• <i>Erik Rosen shall receive NOK 75,000</i></li> </ul>  |
| <p style="text-align: center;">* * *</p>   | <p style="text-align: center;">* * *</p>  |
| <p>Dersom du/dere ønsker å delta på generalforsamlingen ber vi om at vedlagte møteseddel sendes til post@lytixbiopharma.com innen 10. april 2026 kl. 13:00 (CEST). Eiere av forvalterregistrerte aksjer må gi slik melding innen fristen (to virkedager før generalforsamlingen) for å kunne delta på generalforsamlingen, jf. aksjeloven § 4-4 (3) c), jf. allmennaksjeloven § 5-10.</p>                        | <p>Shareholders who want to attend the general meeting are requested to complete the attendance slip and send it by e-mail to post@lytixbiopharma.com by 10 April 2026 at 13:00 hours (CEST). Owners of nominee registered shares must give such notice within the deadline (two business days prior to the general meeting) in order to participate at the general meeting, cf. Section 4-4 (3) c) of the Companies Act, cf. Section 5-10 of the Norwegian Public Limited Liability Companies Act.</p> |
| <p>Aksjeeiere som ikke ønsker å delta på generalforsamlingen henstilles om å fylle ut vedlagte fullmaktsskjema og sende det til post@lytixbiopharma.com innen 10. april 2026 kl. 13:00 (CEST). Hvis det fremmes nye forslag til vedtak som erstatter, supplerer eller på annen måte endrer forslagene i innkallingen, avgjør fullmektigen om og i tilfelle hvordan stemmeretten skal utøves.</p>                 | <p>Shareholders who do not wish to attend the general meeting are recommended to complete the enclosed power of attorney and return it to post@lytixbiopharma.com, within 10 April 2026 at 13:00 hours (CEST). If new proposals are put forward, which replace, supplement or in any way amend the proposals in the</p>   |

|   |   |
|---|---|
|   | agenda, the proxy decides if and how the right to vote should be exercised.   |
| Aksjonærer som ønsker å delta elektronisk på generalforsamlingen bes ta kontakt med Selskapet på post@lytixbiopharma.com innen 10. april 2026 kl. 13:00 (CEST).   | Shareholders who wish to participate electronically at the general meeting are asked to contact the Company at post@lytixbiopharma.com within 10 April 2026 at 13:00 hours (CEST).  |
| Kun de som er aksjeeiere i Selskapet fem virkedager før generalforsamlingen, dvs. den 7. april 2026 (" <b>Registreringsdatoen</b> "), har rett til å delta og stemme på generalforsamlingen, jf. aksjeloven § 4-4 (3) a). En aksjeeier som ønsker å delta og stemme på generalforsamlingen, må være innført i aksjeeierregisteret (VPS) på Registreringsdatoen eller ha meldt og godtgjort erverv per Registreringsdatoen. Aksjer som er ervervet etter Registreringsdatoen gir ikke rett til å delta og stemme på generalforsamlingen. | Only those who are shareholders in the Company five business days prior to the general meeting, i.e. on 7 April 2026 (the " <b>Record Date</b> "), are entitled to attend and vote at the general meeting, cf. Section 4-4 (3) a) of the Companies Act. A shareholder who wishes to attend and vote at the general meeting must be registered in the shareholder register (VPS) at the Record Date or have reported and documented an acquisition as per the Record Date. Shares that are acquired after the Record Date do not entitle the holder to attend and vote at the general meeting. |
| * * *   | * * *   |

24. mars 2026 / 24 March 2026

**På vegne av styret / On behalf of the Board of Directors of  
Lytix Biopharma AS**

\_\_\_\_\_  
Eric Falcand

*Styrets leder / Chair of the board*

| <b>Vedlegg:</b>   | <b>Appendices:</b>   |
|---|--|
| 1. Årsregnskap, årsberetning og revisjonsberetning for 2025 | 1. Annual accounts, annual report and auditors report for 2025 |
| 2. Innstilling fra valgkomitéen                             | 2. The Nomination Committee's recommendation                   |
| 3. Møte- og fullmaktsskjema                                 | 3. Attendance slip and power of attorney form                  |

**Vedlegg 1 / Appendix 1** – Årsregnskap, årsberetning og revisjonsberetning for 2025 / Annual accounts, annual report and auditor's report for 2025

Årsrapporten, som inkluderer årsregnskap, styrets årsberetning og revisjonsberetning for 2025 er tilgjengelig på Selskapets nettsted, <https://www.lytixbiopharma.com/investors/financial-reports.html>.

The annual report, including the annual accounts, the Board of Directors' report and the auditor's report for 2025 is available on the following website: <https://www.lytixbiopharma.com/investors/financial-reports.html> .

# Recommendation from the Nomination and Compensation Committee – Lytix Biopharma AS

## To be presented at the Annual General Meeting 2026

Lytix Biopharma AS is a company in continuous evolution, with 2026 marking a pivotal phase in its development. This progress is characterized by robust clinical results and a validated technology platform that addresses significant unmet needs in cancer treatment. As the company moves closer to late-stage development and potential commercialization, it is essential to ensure that the composition of the Board of Directors reflects the competencies required to support this trajectory.

## Committee Mandate

The Nomination and Compensation Committee (NCC) is tasked with nominating candidates for the Board of Directors and the Nomination and Compensation Committee, providing guidance on employee representation, and proposing remuneration for both the Board and the NCC.

## Review Process

The current board structure was largely changed in 2025. In light of Lytix's progress and future ambitions, the Committee has undertaken a thorough and diligent review of the board's composition. This process included consultations with current board members, company management, major shareholders, industry experts, and potential new candidates.

## Current members of the Board

- **Eric Falcand Chair** - *Business development, commercial insight oncology*
- **Julie Dehaene-Puype** - *Large pharma, biotech, regulatory knowledge*
- **Claus Andersson** - *Fundraising, venture capital, dealmaking skills*
- **Darlene Deptula-Hicks** - *international fundraising, dealmaking skills*
- **Marie-Louise Fjällskog** - *Clinical trials oncology, continuity*
- **Brynjar Forbergskog** - *Strategic leadership, financial oversight, investor perspective*
- **Kjetil Hestdal** - *Clinical development, regulatory strategy, biotech leadership*

In connection with Lytix Biopharma's planned conversion to an ASA company, Darlene Deptula-Hicks was elected to the Board in January 2026 in order to ensure that the company meets the statutory gender balance requirements applicable to Norwegian ASA companies.

### **Proposed Board Composition**

Following its review, the Committee proposes to reduce the Board from seven to six members in order to maintain an efficient and appropriately sized Board, while preserving the key competencies required for the Company's next phase.

The Committee proposes that the following candidates are elected as members of the Board of Directors:

- Eric Falcand (Chair)
- Julie Dehaene-Puype
- Claus Andersson
- Darlene Deptula-Hicks
- Marie-Louise Fjällskog
- Brynjar Forbergskog

### **Election Period**

The Committee proposes that all Board members are elected for a uniform term of two years, until the annual general meeting in 2028.

The proposed election implies that any current terms of office are replaced by the new terms set out above.

The Committee considers that a uniform election period provides clarity, predictability and stability in the Company's governance structure. Consequently, the full Board will be up for election at the annual general meeting in 2028.

### **Proposed Board of Directors (2026–2028):**

| <b>Name</b>            | <b>Role</b>  | <b>Term</b> |
|------------------------|--------------|-------------|
| Eric Falcand           | Chair        | AGM 2028    |
| Julie Dehaene-Puype    | Board Member | AGM 2028    |
| Claus Andersson        | Board Member | AGM 2028    |
| Darlene Deptula-Hicks  | Board Member | AGM 2028    |
| Marie-Louise Fjällskog | Board Member | AGM 2028    |
| Brynjar Forbergskog    | Board Member | AGM 2028    |

## Proposed Remuneration – Board of Directors

The Committee proposes that the following annual cash compensation be paid monthly for the period between the AGM in 2026 and the AGM in 2027.

- Chair: NOK 500,000
- Board Members: NOK 325,000 each

This represents an increase from the current annual compensation of NOK 400,000 for the Chair and NOK 300,000 for board members.

The proposed adjustment reflects the Committee's assessment of the increasing workload, responsibilities and time commitment required of the board. It also takes into account the need to attract and retain board members with relevant international experience and expertise in a competitive market environment.

Overall, the Committee considers the proposed remuneration to be balanced and aligned with the Company's development stage and market practice.

## Remuneration Overview

| Name                   | Role         | Annual Fee (NOK) |
|------------------------|--------------|------------------|
| Eric Falcand           | Chair        | 500,000          |
| Julie Dehaene-Puype    | Board Member | 325,000          |
| Claus Andersson        | Board Member | 325,000          |
| Darlene Deptula-Hicks  | Board Member | 325,000          |
| Marie-Louise Fjällskog | Board Member | 325,000          |
| Brynjar Forbergskog    | Board Member | 325,000          |

## Nomination and Compensation Committee – 2026–2027

The Nomination and Compensation Committee proposes that the following members are elected to the Committee for the period until the annual general meeting in 2027:

| Name                   | Role   | Term     |
|------------------------|--------|----------|
| Steinar Thoresen       | Chair  | AGM 2027 |
| Lise von Tangen Jordan | Member | AGM 2027 |
| Erik Rosen             | Member | AGM 2027 |

## Proposed annual remuneration for NCC members:

| Name                   | Role   | Annual Fee (NOK) |
|------------------------|--------|------------------|
| Steinar Thoresen       | Chair  | 90,000           |
| Lise von Tangen Jordan | Member | 75,000           |
| Erik Rosen             | Member | 75,000           |

This represents an increase from the current level of remuneration.

The proposed adjustment reflects the Committee's assessment of an increased workload and responsibility, including work related to board composition, succession planning and remuneration matters. The Committee considers the proposed remuneration to be appropriate in light of the expected activity level.

**Oslo, 23 March 2026**

*On behalf of the Nomination and Compensation Committee*

Steinar Thoresen

Lise von Tangen-Jordan

Erik Rosen

## The Board of Directors 2026-27

**Eric Falcand** has a strong scientific foundation complemented by recognized leadership, strategic, and operational expertise, Mr. Falcand brings over 37 years of international experience in the pharmaceutical industry, spanning M&A and Business Development (15 years), General Management (10 years), and Commercialization (12 years).

He most recently served as Vice President and Global Head of Business Development and M&A at Servier Group, where he led transformative oncology transactions, including the acquisitions of Agios Oncology (USD 2B), Shire Oncology (USD 2.4B), and Symphogen. These deals significantly strengthened Servier's portfolio in immuno-oncology, positioning the company as a global oncology player. He also led over 50 licensing and partnership agreements globally, many of which focused on oncology and immuno-oncology innovations.

Mr. Falcand has held senior leadership positions in the UK, Russia, Northern Europe, and the US, providing him with deep operational and commercial insight across markets. In addition to his executive experience, he currently serves on the boards of several biotech companies, including NETRIS Pharma and CYTEA/Bio, both active in oncology.

Mr. Falcand's strategic vision and global perspective make him a valuable contributor to companies advancing cutting-edge therapies, particularly within the immuno-oncology field. Mr. Falcand holds a Doctorate in Veterinary Medicine from Lyon, France, and a Master's degree in Pharmaceutical Management.

**Julie Dehaene-Puype** is a pharmaceutical professional with 25 years' experience in General Management, Commercial Operations, Sales & Marketing, New Products Development, Market Research and Regulatory Affairs in companies like MSD and Takeda. She has 10+ years of P&L responsibility at country and regional level. Demonstrated human-centred and inspiring leadership, with proven track record of success in strategic and operational roles in country, region and HQ, in the USA and Europe/Canada. Ms. Dehaene-Puype has a master in Pharmaceuticals Regulatory Affairs from the University of Lille, France.

**Claus Andersson** is applying 25+ years of venture experience with a focus on financing strategies and listed assets in life sciences. Navigating complex financial landscapes, including IPOs and structured transactions, to support sustainable growth in promising companies. Experienced in development strategy, transaction structuring, and public listings to create value particular in oncology and cardiology companies. Adding experience and best practice from more than 20 international boards over the last 25 years. Mr. Andersson is MSc, Civil engineering organic chemistry (Technical University of Denmark, Denmark), PhD, mathematical and multivariate statistics (Humboldt University & Weierstrass Institute for Stochastics and Pseudo Differential Equations, Germany).

**Marie-Louise Fjällskog** has more than 25 years of experience in clinical oncology, translational research, and drug development. Current assignments include being a board member at Faron Pharmaceuticals and Biovica International. Her prior experience includes CMO at Faron Pharmaceuticals, CMO at Sensei Biotherapeutics in Boston, USA, Global Clinical Program Leader at Novartis Institute for Biomedical Research (NIBR), where she worked with Translational Clinical Oncology (TCO). She was Vice President (VP) of Clinical Development at Merus and Infinity Pharmaceuticals, Cambridge, USA. Ms. Fjällskog is a MD PhD (specialist in oncology), from Uppsala University, became an Associate Professor of Oncology in 2008.

**Brynjar Forbergskog** is the CEO of his privately owned investment company, Saturn Invest AS and serves on the board of several companies. He previously held the positions of Chief Financial Officer and subsequently Chief Executive Officer of Torghatten ASA. Under his leadership, Torghatten ASA evolved from a small, locally based transport provider into one of the largest transportation groups in the Nordic region, with over 7,000 employees and an annual turnover exceeding NOK 11 billion. In 2021, Torghatten ASA was sold to EQT for NOK 8.6 billion, marking a successful and value-creating exit under his tenure.

**Darlene Deptula-Hicks** brings extensive international experience as a Chief Financial Officer in listed and private biotechnology companies, with a proven track record in public offerings, strategic transactions, and value-creating exits. Most notably, she served as CFO of F-star Therapeutics, leading the company through its IPO in 2020 and subsequently through its successful acquisition in 2023. In addition, she has acted as CFO or strategic advisor to several biotechnology companies through critical financing, partnering, and M&A processes.

Deptula-Hicks currently serves on multiple biotech boards and has significant experience as Audit Committee Chair, providing strong competencies in financial governance, reporting, capital markets interaction, and board oversight.

**PÅMELDING – ORDINÆR GENERALFORSAMLING 14. april 2026 I LYTIX BIOPHARMA AS**

Melding om at du vil delta i den ordinære generalforsamlingen gis ved å benytte denne møteseddel. Det bes om at signert skjema sendes til [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com) senest den 10. april 2026, kl. 13:00. Dersom du etter påmelding skulle bli forhindret fra å møte, kan skriftlig og datert fullmakt leveres på den ordinære generalforsamlingen.

Undertegnede vil møte på den ordinære generalforsamlingen i Lytix Biopharma AS den 14. april 2026 og (sett kryss):

- Avgi stemme for mine/våre aksjer
  
- Avgi stemme for aksjer ifølge vedlagte fullmakt(er)

Navn på aksjonær / selskap (blokkbokstaver): \_\_\_\_\_

Antall egne aksjer: \_\_\_\_\_

Antall aksjer som eventuelt representeres etter fullmakt: \_\_\_\_\_

\_\_\_\_\_  
dato

\_\_\_\_\_  
sted

\_\_\_\_\_  
aksjonærens underskrift

*Generalforsamlingen avholdes som et fysisk møte, og vi oppfordrer aksjonærene til å gi fullmakt eller delta fysisk. Dersom noen aksjonærer i stedet ønsker å delta elektronisk, ber vi om at dere sender en e-post til [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com) innen 10. april 2026 klokken 13:00 (CET), slik at vi kan legge til rette for dette.*

---

**REGISTRATION – ANNUAL GENERAL MEETING 14 April, 2026 IN LYTIX BIOPHARMA AS**

Notice of attendance at the Annual General Meeting is asked to be sent via this attendance slip. Kindly submit the signed notice by email to [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com) no later than 10 April 2026, 13:00 CEST. If you are unable to attend after you have registered, a written and dated proxy can be submitted at the annual general meeting.

The undersigned will attend the Annual general meeting of Lytix Biopharma AS 14 April 2026 and (tick-off):

Vote for my/our shares

Vote for shares pursuant to enclosed proxy(ies)

Shareholder's name / company name (capital letters): \_\_\_\_\_

Number of own shares: \_\_\_\_\_

Number of shares represented by proxy: \_\_\_\_\_

\_\_\_\_\_  
Date

\_\_\_\_\_  
Place

\_\_\_\_\_  
Shareholder's signature

The general meeting is held as a physical meeting, and we encourage shareholders to give proxy, or participate physically. If any shareholders would instead like to participate electronically, we ask that you send an e-mail to [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com) by 10 April 2026 at 13:00 hours (CET) so that we can accommodate for this.

# LYTIX BIOPHARMA AS

## FULLMAKTSSKJEMA TIL ORDINÆR GENERALFORSAMLING DEN 14. april 2026

Aksjeeiere som ikke selv møter på den ordinære generalforsamlingen i Lytix Biopharma AS den 14. april 2026, bes om å fylle ut denne fullmakten og sende den **per e-post til [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com)**.

Fullmaktsskjema bes sendes slik at det er kommet frem til Selskapet **senest den 10. april 2026 13:00 (CET)**.

Undertegnede gir herved (sett kryss):

CEO, Øystein Rekdal, eller den han bemyndiger

Den som skal lede generalforsamlingen

\_\_\_\_\_  
Navn på fullmektig

fullmakt til å møte og representere meg/oss på den ordinære generalforsamlingen i Lytix Biopharma AS den 14. April 2026. Dersom det er sendt inn fullmakt uten avkryssing ovenfor, anses fullmakten gitt til CEO, Øystein Rekdal, eller den han bemyndiger.

Stemmegivningen skal skje i henhold til instruksjonene nedenfor. Merk at **dersom det ikke er kryssset av i rubrikkene nedenfor, vil dette anses som en instruks om å stemme "for" forslagene i innkallingen**, likevel slik at fullmektigen avgjør stemmegivningen i den grad det blir fremmet forslag i tillegg til, til erstatning for, eller som endring i forslagene i innkallingen.

| Agenda ordinær generalforsamling |  | For                      | Mot                      | Avstå                    |
|----------------------------------|--|--------------------------|--------------------------|--------------------------|
| 1.                               | Valg av møteleder  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 2.                               | Valg av en person til å medundertegne protokollen sammen med møtelederen | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 3.                               | Godkjenning av innkalling og dagsorden                                   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 4.                               | Godkjenning av årsregnskapet og årsberetningen for regnskapsåret 2025    | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 5.                               | Utbytte  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 6.                               | Godkjenning av revisors godtgjørelse                                     | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 7.                               | Styrefullmakt til kapitalforhøyelse - Opsjonsprogrammet                  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 8.                               | Valg av styremedlemmer   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 9.                               | Valg av medlemmer til valgkomiteen                                       | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 10.                              | Honorar til styrets medlemmer  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 11.                              | Honorar til medlemmer av valgkomiteen                                    | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

Navn på aksjonær / selskap (blokkbokstaver): \_\_\_\_\_

Antall aksjer: \_\_\_\_\_

\_\_\_\_\_  
Dato

\_\_\_\_\_  
Sted

\_\_\_\_\_  
Aksjonærens underskrift

Dersom aksjeeieren er et selskap, eller annen juridisk enhet, skal dokumentasjon i form av firmaattest, og eventuelt fullmakt, vedlegges fullmakten.

# LYTIX BIOPHARMA AS

## PROXY FORM TO THE ORDINARY GENERAL MEETING ON 14 April 2026

Shareholders who will not attend the ordinary general meeting on 14 April 2026 in person, are asked to complete this proxy form and return it **per e-mail to [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com)**.

The proxy form should be received by the Company **no later than 10 April 2026 at 13:00 hours (CET)**.

The undersigned hereby grants (please tick):

The CEO, Øystein Rekdal, or the person he appoints

The chairperson of the general meeting

\_\_\_\_\_  
Name of proxy

power of attorney to attend and vote for my/our shares at the ordinary general meeting of Lytix Biopharma AS to be held on 14 April 2026. If the proxy form is submitted without ticking of the box above, the proxy will be deemed to have been given to the CEO, Øystein Rekdal, or the person he appoints.

The votes shall be cast in accordance with the instructions below. Please note that **if the alternatives below are not ticked off, this will be deemed to be an instruction to vote "in favour" of the proposals in the notice**, provided, however, that the proxy holder determines the voting to the extent proposals are put forward in addition to, instead of, or as adjustments to the proposals in the notice.

| Agenda for the ordinary general meeting |  | For                      | Against                  | Abstention               |
|---|--|--------------------------|--------------------------|--------------------------|
| 1.                                      | Election of a person to chair the meeting  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 2.                                      | Election of a person to co-sign the minutes together with the chair of the meeting | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 3.                                      | Approval of Notice and agenda  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 4.                                      | Approval of the annual accounts and the annual report for the financial year 2025  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 5.                                      | Distribution of dividend   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 6.                                      | Approval of the auditor's remuneration   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 7.                                      | Board authorization for share capital increase                                     | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 8.                                      | Election of members to the board of directors                                      | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 9.                                      | Election of members to the nomination committee                                    | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 10.                                     | Remuneration to the members of the board of directors                              | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 11.                                     | Remuneration to the members of the nomination committee                            | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

Shareholder's name (capital letters): \_\_\_\_\_

Number of shares: \_\_\_\_\_

\_\_\_\_\_  
Date

\_\_\_\_\_  
Place

\_\_\_\_\_  
Shareholder's signature

If the shareholder is a legal entity, please attach documentation in the form of certificate of registration, or separate power of attorney, if applicable, to this power of attorney.